BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pascual T, Oliveira M, Villagrasa P, et al. (2021) Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Npj Breast Cancer. 7: 145 |
| Smyth LM, Batist G, Meric-Bernstam F, et al. (2021) Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Npj Breast Cancer. 7: 44 |
| Arruabarrena-Aristorena A, Maag JLV, Kittane S, et al. (2020) FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell |
| Xu J, Higgins MJ, Tolaney SM, et al. (2020) A phase II trial of cabozantinib in hormone-receptor positive breast cancer with bone metastases. The Oncologist |
| Smyth LM, Tamura K, Oliveira M, et al. (2020) Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With -Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Subbiah V, Puzanov I, Blay JY, et al. (2020) Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery |
| Xu G, Chhangawala S, Cocco E, et al. (2020) ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature Genetics |
| Mondello P, Tadros S, Teater M, et al. (2020) Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery |
| Bines J, Procter M, Restuccia E, et al. (2019) Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clinical Breast Cancer |
| Smyth LM, Piha-Paul SA, Won HH, et al. (2019) Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery |